Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2019

Open Access 01-12-2019 | Migraine | Review article

How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice

Authors: Cindy Tiseo, Raffaele Ornello, Francesca Pistoia, Simona Sacco

Published in: The Journal of Headache and Pain | Issue 1/2019

Login to get access

Abstract

Background

Migraine is a major public health issue associated with significant morbidity, considerable negative impact on quality of life, and significant socioeconomic burden. Preventive treatments are required to reduce the occurrence and the severity of acute attacks and to minimize the use of abortive medications and the associate risk of drug-related adverse events, as well as the onset of medication-overuse headache and chronification of migraine. We performed a review of all available evidence on the safety and efficacy of monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor for the preventive treatment of migraine to provide evidence-based guidance on their use in clinical practice.

Abstract main body

Monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor are mechanism-specific drugs for the preventive treatment of migraine. Double-blind randomized clinical trials have shown that monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor are effective across all the spectrum of migraine patients who require prevention and have a good safety and tolerability profile. Nevertheless, high costs limit the affordability of those drugs at the moment.

Conclusions

Specificity, long half-life, efficacy, tolerability, and ease of use make monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor an appealing treatment option for migraine prevention. Optimal strategies to manage treatment over time still need to be clarified with real-life data.
Literature
1.
GBD 2015 Disease and injury incidence and prevalence collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545–1602CrossRef
2.
3.
Victor T, Hu X, Campbell J, Buse D, Lipton R (2010) Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 30:1065–1072PubMedCrossRef
4.
Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population - burden, diagnosis, and satisfaction with treatment. Neurology. 71:559–566PubMedCrossRef
5.
Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM (1982) Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 15(298):240–244CrossRef
6.
Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J, Vale WW, Evans RM (1983) Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 304:129–135PubMedCrossRef
7.
Goadsby PJ (2016) Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients. Brain. 139:2571–2577PubMedCrossRef
8.
Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6:573–582PubMedCrossRef
9.
Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187PubMedCrossRef
10.
Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56PubMedCrossRef
11.
Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, Szolcsanyi J, Vitrai J, Bagdy G (2003) NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 106:461–470PubMedCrossRef
12.
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia. 22:54–61PubMedCrossRef
13.
Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J (2005) BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77:202–213PubMedCrossRef
14.
Edvinsson L, Warfvinge K (2017) Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 39:366–73PubMedCrossRef
15.
Olesen J, Burstein R, Ashina M, Tfelt-Hansen P (2009) Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 8:679–690PubMedCrossRef
16.
González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM (2018) Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol 14:25–41PubMedCrossRef
17.
Edvinsson L (2017) The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 57:47–55PubMedCrossRef
18.
Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J (2014) ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100–1107PubMedCrossRef
19.
Saper J, Lipton R, Kudrow D, Hirman J, Dodick D, Silberstein S, Chakhava G, Smith J (2018) Primary results of PROMISE-1 (PRrevention of migraine via intravenous eptinezumab safety and efficacy–1) trial: a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraines. Neurology. 90(15 Supplement):S20.001
20.
Silberstein S, McAllister P, Berman G, Cady R, Smith J, Biondi D, Hirman J (2018) Eptinezumab reduced migraine frequency, duration, and pain intensity through week 24: results from the phase 3 PROMISE-1 trial. Neurology. 90(15 Supplement):4091
21.
Smith T, Biondi D, Berman G, Freeman M, Hirman J, Kassel E (2018) Eptinezumab achieved meaningful reductions in migraine activity within 24 hours that were sustained through week 12: results from PROMISE-1 (prevention of migraine via intravenous eptinezumab safety and Efficacy-1) phase 3 trial. Neurology. 90(15 Supplement):4.092
22.
Lipton RB, Saper J, Ashina M, Biondi D, Bhattacharya S, Hirman J, Schaeffler B, Cady R (2018) A phase 3 study to evaluate eptinezumab for the preventive treatment of chronic migraine: results of the PROMISE-2 (PRevention of migraine via intravenous Eptinezumab safety and Efficacy-2) trial. Headache. 50(S2):PF02
23.
Winner PK, Goadsby P, Nagy A, Brandes J, Biondi D, Bhattacharya S, Cady R, Hirman J, Kassel E (2018) Eptinezumab reduced migraine activity and achieved high migraine responder rates over weeks 1-12: results from the phase 3 PROMISE-2 trial in chronic migraine. Headache. 50(S2):IOR03
24.
Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377:2123–2132CrossRefPubMed
25.
Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 38:1026–1037PubMedCrossRef
26.
Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425–434PubMedCrossRef
27.
Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 319:1999–2008PubMedCrossRef
28.
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:2113–2122PubMedCrossRef
29.
Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75:1080–1088PubMedPubMedCentralCrossRef
30.
Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 38:1442–1454PubMedCrossRef
31.
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 91:e2211–e2221PubMedPubMedCentralCrossRef
32.
Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW (2018) Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 75:187–193PubMedCrossRef
33.
Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME (2019) The effect of beginning treatment with fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: post-hoc analyses on the first 3 weeks of treatment. Headache. 59:383–393.CrossRef
34.
Brandes JL, Yeung PP, Aycardi E, Yang R, Ma Y, Cohen JM (2018) The impact of fremanezumab on symptoms associated with migraine in patients with episodic migraine. J Headache Pain. 19(Suppl 1):P3
35.
McAllister P, Yeung PP, Aycardi E, Yang R, Ma Y, Cohen JM (2018) The impact of fremanezumab on symptoms associated with migraine in patients with chronic migraine. J Headache Pain. 19(Suppl 1):P4
36.
Day KA, Ament M, Stauffer VL, Skljarevski V, Zhang Q, Pearlman EM, Aurora SK (2018) Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. J Headache Pain. 19(Suppl 1):O31
37.
Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootell RB, Sorensen AG, Moskowitz MA (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 98:4687–4692PubMedPubMedCentralCrossRef
38.
Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808CrossRef
39.
Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal. J Headache Pain. 20:6PubMedCrossRefPubMedCentral
40.
Uddman R, Edvinsson L, Ekblad E, Håkanson R, Sundler F (1986) Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 15:1–23PubMedCrossRef
41.
MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD (2016) Wiping Out CGRP: Potential cardiovascular risks. Trends Pharmacol Sci 37(9):779–788PubMedCrossRef
42.
Ohlsson L, Kronvall E, Stratton J, Edvinsson L (2018) Fremanezumab blocks CGRP induced dilatation in human cerebral middle meningeal and abdominal arteries. J Headache Pain. 19:66PubMedPubMedCentralCrossRef
43.
Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, Mikol DD (2018) A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 58:715–723PubMedPubMedCentralCrossRef
44.
Tepper S, Pascual J, Reuter U, Picard H, Hong F, Trotman ML, Xue F, Mikol DD, Klatt J (2018) Analysis of blood presuure following erenumab treatment. Analysis of blood pressure following short-term and long-term treatment with erenumab. Neurology 90(15 Supplement):4.103
45.
Tepper S, Broessner G, Buse G, Schwedt T, Strauss E, Zhang F, Picard H, Mikol D (2018) Efficacy of erenumab for the treatment of patients with episodic migraine with depression and/or anxiety. Neurology. 90(15 Supplement):4.105
46.
Cohen JM, Yeung PP, Aycardi E, Bigal ME, Yang R, Bibeau K, Galic M, Seminerio MJ, Lipton RB, Buse DC (2018) Efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to moderately severe depression. Neurology. 90(15 Supplement):4.097
47.
48.
Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Mikol D (2017) Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s). Cephalalgia. 37(Suppl 1):13
49.
Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 38:1611–1621PubMedCrossRef
50.
Winner PK, Singh RBH, Cohen JM, Yang R, Yeung PP, Campos VR (2018) Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication. J Headache Pain. 19(Suppl 1):O38
51.
Silberstein SD, Ailani J, Cohen JM, Yang R, Yeung PP, Campos VR (2018) Impact of fremanezumab on response rates, migraine days, and acute medication use in patients with chronic migraine who have failed at least one prior migraine preventive medication. J Headache Pain. 19(Suppl 1):O39
52.
Dell’Agnello G, Tockhorn-Heidenreich A, Zhang Q, Ruff DD, Pearlman EM, Aurora SK, Ford JH (2018) Efficacy of galcanezumab in patients who failed prior preventive treatments for migraine: results from EVOLVE-1, EVOLVE-2 and REGAIN studies. J Headache Pain. 19(Suppl 1):O19
53.
Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 392:2280–2287PubMedCrossRef
54.
Ailani J, Pearlman E, Zhang Q, Nagy AJ, Schuh K, Aurora SK (2018) Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine. Poster PS106LB presented at the American Headache Society (AHS), San Francisco
55.
de Goffau MJ, Klaver ARE, Willemsen MG, Bindels PJE, Verhagen AP (2017) The effectiveness of treatments for patients with medication overuse headache: a systematic review and meta-analysis. J Pain 18:615–627PubMedCrossRef
56.
Silberstein SD, Ashina S, Katsarava Z, Bibeau K, Seminerio MJ, Harlow DE, Cohen JM (2018) The impact of fremanezumab on medication overuse in patients with chronic migraine. J Headache Pain. 19(Suppl 1):12
57.
Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, Bigal ME (2017) Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache. 57:1375–1384PubMedCrossRef
58.
Goadsby PJ, Dodick DW, Silberstein SD, Yeung PP, Blankenbiller T, Ning X, Yang R, Ma Y, Aycardi E, Bigal ME (2018) Efficacy of fremanezumab in patients with chronic migraine with or without concomitant use of preventive medication. J Headache Pain. 19(Suppl 1):8
59.
Rendas-Baum R, Yang M, Varon SF, Bloudek LM, DeGryse RE, Kosinski M (2014) Validation of the headache impact test (HIT-6) in patients with chronic migraine. Health Qual Life Outcomes 12:117PubMedPubMedCentralCrossRef
60.
Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical utility of an instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire. Headache. 41(9):854–861PubMedCrossRef
61.
Kawata AK, Hsieh R, Bender R, Shaffer S, Revicki DA, Bayliss M, Buse DC, Desai P, Sapra S, Ortmeier B, Hareendran A (2017) Psychometric evaluation of a novel instrument assessing the impact of migraine on physical functioning: the migraine physical function impact diary. Headache. 57:1385–1398PubMedCrossRef
62.
Cole JC, Lin P, Rupnow MFT (2007) Validation of the migraine-specific quality of life questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res 16:1231–1237PubMedCrossRef
63.
Guy W (1976) ECDEU assessment manual for psychopharmacology, revised. National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, pp 217–222
64.
Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G, Boudreau GP, McAllister P, Vu T, Zhang F, Cheng S, Picard H, Wen S, Kahn J, Klatt J, Mikol D (2018) Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 19:92PubMedCrossRefPubMedCentral
65.
Aurora SK, Detke HC, Millen BA, Hundemer HP (2018) Rapid onset of effect of galcanezumab for the prevention of episodic migraine: post-hoc analyses of two phase 3 studies. J Headache Pain. 19(Suppl 1):132
66.
Nichols R, Doty E, Sacco S, Ruff D, Pearlman E, Aurora SK (2019) Analysis of initial nonresponders to galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE-1, EVOLVE-2, and REGAIN randomized, double-blind, placebo-controlled studies. Headache. 59:192–204PubMedCrossRef
67.
Gingell JJ, Hendrikse ER, Hay DL (2019) New insights into the regulation of CGRP-family receptors. Trends Pharmacol Sci 40:71–83PubMedCrossRef
68.
Detke HC, Li LQ, Wang S, Aurora SK (2018) One-year treatment with galcanezumab in patients with chronic migraine: results from the open-label phase of the REGAIN study. Cephalalgia. 38(1S):149
69.
Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL (2018) A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol 18:188PubMedPubMedCentralCrossRef
70.
Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Zhang F, Cheng S, Mikol D (2018) Assessment of the long-term safety and efficacy of erenumab during open-label treatment of subjects with chronic migraine. J Headache Pain 19(Suppl 1):24
71.
Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA (2017) Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology. 89:1237–1243PubMedCrossRef
72.
Brandes JL, Yeung PP, Cohen JM, Gandhi SK, Fitzgerald T, Yang R, Ma Y, Aycardi E (2018) Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: interim results of a 1-year study. J Headache Pain 19(Suppl 1):5
73.
Zhang Q, Morrow PA, Stauffer VL, Skljarevski V, Pearlman EM, Aurora SK (2018) Effect of galcanezumab following double-blind treatment in patients with migraine: results from EVOLVE-1 and EVOLVE-2. J Headache Pain 19(Suppl 1):19
74.
Silberstein S, Lenz R, Xu C (2015) Therapeutic monoclonal antibodies: what headache specialists need to know. Headache. 55:1171–1182PubMedCrossRef
75.
Khalil Z, Helme R (1996) Sensory peptides as neuromodulators of wound healing in aged rats. J Gerontol A Biol Sci Med Sci 51:B354–B361PubMedCrossRef
76.
Sun YD, Benishin CG (1991) Effects of calcitonin gene-related peptide on longitudinal muscle and myenteric plexus of Guinea pig ileum. J Pharmacol Exp Ther 259:947–952PubMed
77.
78.
Juul R, Edvinsson L, Gisvold SE, Ekman R, Brubakk AO, Fredriksen TA (1990) Calcitonin gene-related peptide-LI in subarachnoid haemorrhage in man. Signs of activation of the trigemino-cerebrovascular system? Br J Neurosurg 4:171–179PubMedCrossRef
79.
Smillie SJ, King R, Kodji X, Outzen E, Pozsgai G, Fernandes E, Marshall N, de Winter P, Heads RJ, Dessapt-Baradez C, Gnudi L, Sams A, Shah AM, Siow RC, Brain SD (2014) An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension. 63:1056–1062PubMedCrossRef
80.
Saetrum Opgaard O, Hasbak P, de Vries R, Saxena PR, Edvinsson L (2000) Positive inotropy mediated via CGRP receptors in isolated human myocardial trabeculae. Eur J Pharmacol 397:373–382PubMedCrossRef
81.
Sacco S, Cerone D, Carolei A (2008) Comorbid neuropathologies in migraine: an update on cerebrovascular and cardiovascular aspects. J Headache Pain 9:237–248PubMedPubMedCentralCrossRef
82.
Sacco S, Pistoia F, Degan D, Carolei A (2015) Conventional vascular risk factors: their role in the association between migraine and cardiovascular diseases. Cephalalgia. 35:146–164PubMedCrossRef
83.
Sacco S, Kurth T (2014) Migraine and the risk for stroke and cardiovascular disease. Curr Cardiol Rep 16:524PubMedCrossRef
84.
Sacco S, Ripa P, Grassi D, Pistoia F, Ornello R, Carolei A, Kurth T (2013) Peripheral vascular dysfunction in migraine: a review. J Headache Pain. 14:80PubMedPubMedCentralCrossRef
85.
Majima M, Ito Y, Hosono K, Amano H (2019) CGRP/CGRP receptor antibodies: potential adverse effects due to blockade of neovascularization? Trends Pharmacol Sci 40:11–21PubMedCrossRef
Metadata
Title
How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
Authors
Cindy Tiseo
Raffaele Ornello
Francesca Pistoia
Simona Sacco
Publication date
01-12-2019
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2019
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-019-1000-5

Other articles of this Issue 1/2019

The Journal of Headache and Pain 1/2019 Go to the issue

Research article

Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic

Research article

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

Research article

Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications

Research article

Burden of headache disorders in China, 1990–2017: findings from the Global Burden of Disease Study 2017

Correction

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Review article

Mechanisms of migraine as a chronic evolutive condition